CUA Health signs contract extension with Flamingo Ai
Flamingo Ai Limited (ASX:FGO) has inked a contract extension with major client, CUA Health Ltd (a subsidiary of Credit Union Australia), to extend its use of FGO’s Cognitive Virtual Sales Assistant, ‘Sam’.
Sam guides CUA Health’s customers through their full health insurance purchase experience and transaction. The insurance provider has been trialling Sam live with potential health insurance customers for the past two months.
Based on encouraging results, CUA Health has decided to bring forward the end of the trial date (12 November) and sign an extension of contract with FGO — inclusive of a monthly subscription fee for the Virtual Sales Assistant for health insurance, effective immediately.
FGO stated in its announcement that the details of the monthly fee are commercially sensitive.
The relationship has considerable potential for FGO’s growing sales pipeline, and validates its technology since CUA is a key player in the small cap’s target insurance market.
During the newly announced extension of the trial, CUA Health will explore opportunities to expand the health insurance pilot of Sam to new sales distribution scenarios and determine whether there may be other future use cases for the tech play within the broader business.
“We have seen some excellent early results from guiding members through the online purchase journey. Sales conversion has improved and Sam is now able to sell policies independently when appropriate to do so,” CUA Health National Sales & Marketing Manager, Richard Martin, said.
“A longer period of analysis, based on the extended pilot, will allow us to seek further improvements in member experience and conversion, plus test the technology in a different environment.”
CUA Head of Digital Innovation, Melissa Witheriff, added: “Exploration of new technologies such as AI and Machine learning are part of our digital innovation strategy. CUA has placed significant focus on investing in innovation and seeking out collaborative opportunities with partners.
“Working with the Flamingo Ai team has enabled our health business to respond to changing consumer expectations through human centred design. By enhancing the online experience for consumers inquiring about health insurance, we’ve created an engaging digital channel to attract new members to CUA Health.”
Chief Commercial Officer and Executive Director, Mark Kehoe, also had something to say about today’s major news, reaffirming that the company’s relationship with CUA has never been stronger.
“The deployment of Flamingo’s technology, and the encouraging results we are seeing, have meant that CUA and Flamingo Ai can now plan where this technology may solve problems and add value across CUA’s broader business,” he said.
“In our experience CUA have proven to be highly innovative and have their own customer’s experience being at the heart of what they do. These shared corporate values make for a strong and exciting collaboration between CUA and Flamingo Ai.”
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.